国重头模板--新药研究国家重点实验室
2017年度发表论文
作者:管理员      发表日期: 2018-08-16         打印    【 】  【关闭

  1.      Structure of the full-length glucagon class B G-protein-coupled receptor. Zhang HN, Anna Qiao, Yang DH, Yang LL, Dai AT, Chris de Graaf, Steffen Reedtz-Runge,Venkatasubramanian Dharmarajan, Zhang H, Gye Won Han, Thomas D. Grant, Raymond G. Sierra, Uwe Weierstall,Garrett Nelson, Liu W, Wu YH, Ma LM, Cai XQ, Lin GY, Wu XA, Geng Z, Dong YH, Song GJ, Patrick R. Griffin, Jesper Lau, Vadim Cherezov, Yang HY, Michael A. Hanson,Raymond C. Stevens, Zhao Q, Jiang HL*, Wang MW* and Wu BL*. Nature (2017)546(7657): 259-264········································································· 40.137 

  2.      Ancient hybridization and strong adaptation to viruses across African vervet monkey populations.Hannes Svardal, Anna J Jasinska, Cristian Apetrei, Giovanni Coppola, Huang Y, Christopher A Schmitt, Beatrice Jacquelin, Vasily Ramensky, Michaela Müller-Trutwin, Martin Antonio, George Weinstock, J Paul Grobler, Ken Dewar, Richard K Wilson, Trudy R Turner, Wesley C Warren, Nelson B Freimer and Magnus Nordborg*.Nat Genet (2017)49: 1705-1713······················································· 27.959 

  3.        Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation.   Lian QS, Xu J, Yan SS, Huang M*, Ding HH, Sun XY, Bi AW, Ding J*, Sun B* and Geng MY*. Cell Res (2017)27: 784-800························································································ 15.605 

  4.        Structural Insights into the Redox-Sensing Mechanism of MarR-Type Regulator AbfR. Liu GJ, Liu X, Xu HJ, Liu XC, Zhou H, Huang Z, Gan JH, Chen H, Lan LF and Yang CG*. J Am Chem Soc (2017)139: 1598-1608········································································· 13.858 

  5.      Polymeric Immunoglobulin Receptor Promotes Tumor Growth in Hepatocellular Carcinoma.Yue XH, Ai J, Xu Y, Chen Y, Huang M, Yang XY, Hu B, Zhang HT, He CX, Yang XR, Tang WG, Peng X, Dong LW, Wang HY, Fan J*, Ding J* and Geng MY*.Hepatology (2017)65(6): 1948-1962····················· 13.246 

  6.      Acidity-Triggered Ligand-Presenting Nanoparticles To Overcome Sequential Drug Delivery Barriers to Tumors. Wang TT, Wang DG, Liu JP, Feng B, Zhou FY, Zhang HW, Zhou L, Yin Q, Zhang ZW, Cao ZL, Yu HJ* and Li YP*.Nano Lett (2017)17: 5429-5436························································· 12.712 

  7.      Inflammatory Monocytes Loading Protease-Sensitive Nanoparticles Enable Lung Metastasis Targeting and Intelligent Drug Release for Anti-Metastasis Therapy.He XY, Cao HQ, Wang H, Tan T, Yu HJ, Zhang PC, Yin Q, Zhang ZW* and Li YP*.Nano Lett (2017)17: 5546-5554·········································· 12.712 

  8.    Cancer Cell Membrane-Coated Gold Nanocages with Hyperthermia-Triggered Drug Release and Homotypic Target Inhibit Growth and Metastasis of Breast Cancer. Sun HP, Su JS, Meng QS, Yin Q, Chen LL, Gu WW, Zhang ZW, Yu HJ, Zhang PC, Wang SL* and Li YP*. Adv Funct Mater (2017)27: 1604300···· 12. 124 

  9.      Albumin Biomimetic Nanocorona Improves Tumor Targeting and Penetration for Synergistic Therapy of Metastatic Breast Cancer. Cao HQ, Zou LL, He B, Zeng LJ, Huang YZ, Yu HJ, Zhang PC, Yin Q, Zhang ZW* and Li YP*. Adv Funct Mater (2017)27: 1605679······················································ 12.124 

  10.    Programmed Multiresponsive Vesicles for Enhanced Tumor Penetration and Combination Therapy of Triple-Negative Breast Cancer. Zhou FY, Feng B, Wang TT, Wang DG, Meng QS, Zeng JF, Zhang ZW, Wang SL, Yu HJ* and Li YP*. Adv Funct Mater (2017)27: 1606530···································· 12. 124 

  11.    Ly6Chi Monocytes Delivering pH-Sensitive Micelle Loading Paclitaxel Improve Targeting Therapy of Metastatic Breast Cancer. Lang TQ, Dong XY, Huang Y, Ran W, Yin Q*, Zhang PC, Zhang ZW, Yu HJ and Li YP*. Adv Funct Mater (2017)27: 1701093···························································· 12.124 

  12.    Theranostic Prodrug Vesicles for Reactive Oxygen Species-Triggered Ultrafast Drug Release and Local-Regional Therapy of Metastatic Triple-Negative Breast Cancer. Zhou FY, Feng B, Wang TT, Wang DG, Cui ZR, Wang SL*, Ding CY, Zhang ZW, Liu J, Yu HJ* and Li YP*. Adv Funct Mater (2017)27: 1703674···· 12.124 

  13.    G9a regulates breast cancer growth by modulating iron homeostasis through the repression of erroxidase hephaestin. Wang YF, Zhang J, Su Y , Shen YY, Jiang DX, Hou YY, Geng MY*, Ding J* and Chen Y*. Nat Commun (2017)8: 274························································································· 12.124 

  14.    An allosteric ligand-binding site in the extracellular cap of K2P channels. Luo QC, Chen LP, Cheng X, Ma YQ, Li XN, Zhang B, Li L, Zhang SL, Guo F, Li Y* and Yang HY*. Nat Commun (2017)8: 378··· 12.124 

  15.    Remote light-controlled intracellular target recognition by photochromic fluorescent glycoprobes.Zhang JJ, Fu YX, Han HH, Zang Y, Li J*, He XP*, Ben L. Feringa and Tian H*. Nat Commun (2017)8: 987 12.124 

  16.    Phosphorylation of Pkp1 by RIPK4 regulates epidermal differentiation and skin tumorigenesis. Lee P, Jiang S, Li Y, Yue J, Gou X, Chen SY, Zhao Y, Schober M, Tan MJ and Wu X*. EMBO J (2017)36(13): 1963-1980······················································································································ 9.792 

  17.    Epithelial EZH2 serves as an epigenetic determinant in experimental colitis by inhibiting TNFα-mediated inflammation and apoptosis. Liu YF, Peng JJ, Sun TY, Li N, Zhang L, Ren JL, Yuan HR, Kan S, Pan Q, Li X, Ding YF, Jiang M, Cong XJ, Tan MJ, Ma YS, Fu D, Cai SJ, Xiao YC, Wang XM and Qin J*. ·· PNAS (2017): E3796-E3805································································································· 9.661 

  18.    c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors. Liu HY, Ai J, Shen AJ, Chen Y, Wang XY, Peng X, Chen H, Shen YY, Huang M*, Ding J* and Geng MY*. Clin Cancer Res (2017)15;23(4): 974-984····························································································· 9.619 

  19.    Aspirin Inhibits Cancer Metastasis and Angiogenesis via Targeting Heparanase. Dai XY, Yan J, Fu XH, Pan QM, Sun DN, Xu Y, Wang J, Nie LT, Tong LJ, Shen AJ, Zheng MY, Huang M, Tan MJ, Liu H, Huang X*, Ding J* and Geng MY*. Clin Cancer Res (2017)23(20): 6267-6278·································· 9.619 

  20.    PI-273, a Substrate-Competitive, Specific Small- Molecule Inhibitor of PI4KIIa, Inhibits the Growth of Breast Cancer Cells. Li JM, Gao Z, Zhao D, Zhang LF, Qiao XH, Zhao YY, Ding H, Zhang PP, Lu JY, Liu J, Jiang HL, Luo C* and Chen C*. Cancer Res (2017)77(22): 6253-6266······························· 9.122 

  21.    Enhanced Blood Suspensibility and Laser-Activated Tumor-specific Drug Release of Theranostic. soporous Silica Nanoparticles by Functionalizing with Erythrocyte Membranes. Su JH, Sun HP, Meng QS, Zhang PC, Yin Q and Li YP*. Theranostics (2017)7(3): 523-537···················································· 8.766 

  22.    Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3Kα-selective Inhibitors in Breast Cancer. Xu YC, Wang X, Chen Y, Chen SM, Yang XY, Sun YM, Geng MY, Ding J* and Meng LH*. Theranostics (2017)7(4): 974-986·················································································· 8.766 

  23.    Preparation and Application of Cell Membrane-Camouflaged Nanoparticles for Cancer Therapy. Zhai YH, Su JH, Ran W, Zhang PC, Yin Q, Zhang ZW, Yu HJ* and Li YP*. Theranostics (2017)7(10): 2575-2592 8.766 

  24.    pH-Sensitive Nano-Complexes Overcome Drug Resistance and Inhibit Metastasis of Breast Cancer by Silencing Akt Expression*.Yin JY, Lang TQ, Cun DM, Zheng Z, Huang Y, Yin Q*, Yu HJ and Li YP*. Theranostics (2017)7(17): 4204-4216············································································· 8.766 

  25.    One-Step Microfluidic Synthesis of Nanocomplex with Tunable Rigidity and Acid-Switchable Surface Charge for Overcoming Drug Resistance. Feng Q, Liu JP, Li XY, Chen QH, Sun JS*, Shi XH, Ding BQ, Yu HJ*, Li YP and Jiang XY*. Small (2017)13: 1603109···················································· 8.643 

  26.    Dual pH-sensitive micelles with charge-switch for controlling cellular uptake and drug release to treat metastatic breast cancer. Tang S, Meng QS, Sun HP, Su JH, Yin Q*, Zhang ZW, Yu HJ, Chen LL, Gu WW and Li YP*. Biomaterials (2017)114: 44-53······························································· 8.402 

  27.    Regulating cancer associated fibroblasts with losartan-loaded injectable peptide hydrogel to potentiate chemotherapy in inhibiting growth and lung metastasis of triple negative breast cancer. Hu CH, Liu XY, Ran W, Meng J, Zhai YH, Zhang PC*, Yin Q, Yu HJ, Zhang ZW and Li YP*. Biomaterials (2017)114: 60-72 8.402 

  28.    m6A RNA Methylation Regulates the Self-Renewal and Tumorigenesis of Glioblastoma Stem Cells. Cui Q, Shi HL, Ye P, Li L, Qu QH, Sun GQ, Sun GH, Lu ZK, Huang Y, Yang CG, Arthur D. Riggs, He C* and Shi YH*. Cell Rep (2017)18: 2622-2634·········································································· 8.282 

  29.    Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells. Qu J, Sun WY, Zhong J, Lv H, Zhu MR, Xu J, Jin N, Xie ZQ, Tan MJ, Lin SH, Geng MY, Ding J* and Huang M*. J Cell Biol (2017)216(2): 409-424···························································· 7.955 

  30.    Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity. Zhang D, Jin N, Sun W, Li X, Liu B, Xie Z, Qu J, Xu J, Yang X, Su Y, Tang S, Han H, Chen D, Ding J, Tan M, Huang M* and Geng MY*.Oncogene (2017)36: 2900-2909·················································· 7.519 

  31.    Supramolecular Polymer Dot Ensemble for Ratiometric Detection of Lectins and Targeted Delivery of Imaging Agents. Wang CZ, Chen JL, Tang Y, Zang Y, Chen GR, Tony D James, Li J*, Wu CF* and He XP*. ACS Appl Mater Inter (2017)9: 3272-3276································································ 7.504 

  32.    GPCR Activation and Endocytosis Induced by a 2D Material Agonist. Dou WT, Kong Y, He XP*, Chen GR, Zang Y*, Li J* and Tian H. ACS Appl Mater Inter (2017)9: 14709-14715·························· 7.504 

  33.    Visible-Light-Driven, Radical-Triggered Tandem Cyclization of o?Hydroxyaryl Enaminones: Facile Access to 3?CF2 /CF3?Containing Chromones. Xiang HY, Zhao QL, Tang ZY, Xiao JN, Xia PJ, Wang CM,Yang CH, Chen XQ*and Yang H*.Org Lett (2017)19: 146-149····················································· 6.579 

  34.    Construction of Chiral Tricyclic Indoles through a Rhodium-Catalyzed Asymmetric Arylation Protocol. Wu CY, Yu YN and Xu MH*. Org Lett (2017)19: 384-387························································ 6.579 

  35.    Taxodikaloids A and B, Two Dimeric Abietane-Type Diterpenoids from Taxodium ascendens Possessing an Oxazoline Ring Linkage. Huang XH, Tao LX, Ke CQ, Tang CP, Zhang HY, Ye Y, Lin LG* and Yao S*. Org Lett (2017)19: 556-559························································································· 6.579 

  36.    Asymmetric Total Synthesis of Distaminolyne A and Revision of Its Absolute Configuration. Sun DY, Han GY, Gong JX, Bastien Nay, Li XW* and Guo YW*. Org Lett (2017)19: 714-717······················· 6.579 

  37.    Fortunoids A?C, Three Sesquiterpenoid Dimers with Different Carbon Skeletons from Chloranthus fortune. Zhou B, Liu QF, Seema Dalal, Maria B. Cassera and Yue JM*. Org Lett (2017)19: 734-737······· 6.579 

  38.    Direct Approach to N?Substituted-2-Fluoroindoles by Sequential Construction of C?N Bonds from gem-Difluorostyrenes. Zhang B, Zhang XF, Hao J* and Yang CH*. Org Lett (2017)19: 1780-1783······ 6.579 

  39.    Highly Enantioselective Arylation of N,N?Dimethylsulfamoyl-Protected Aldimines Using Simple Sulfur?Olefin Ligands: Access to Solifenacin and (S)?(+)-Cryptostyline II. Jiang T, Chen WW and Xu MH*.Org Lett (2017)19: 2138-2141··············································································· 6.579 

  40.    Triconoids A?D, Four Limonoids Possess Two Rearranged Carbon Skeletons from Trichilia connaroides. Wang GC, Fan YY, Sajan L. Shyaula and Yue JM*. Org Lett (2017): 2182-2185······················ 6.579 

  41.    Enantioselective Synthesis of gem-Diaryl Benzofuran-3(2H)?ones viaOne-Pot Asymmetric Rhodium/Palladium Relay Catalysis. Zhang ZF, Zhu DX, Chen WW, Xu B* and Xu MH*. Org Lett (2017)19: 2726-2729·································································································· 6.579 

  42.    Manganese(I)-Catalyzed C?H 3,3-Difluoroallylation of Pyridones andIndoles. Ni JB, Zhao HC and Zhang A*. Org Lett (2017)19: 3159-3162················································································· 6.579 

  43.    Monomeric Octahedral Ruthenium(II) Complex Enabled meta-C?H Nitration of Arenes with Removable Auxiliaries. Fan ZL, Li J, Lu H, Wang DY, Wang C, Masanobu Uchiyama and Zhang A*. Org Lett (2017)19: 3199-3202·································································································· 6.579 

  44.    Xishacorenes A?C, Diterpenes with Bicyclo[3.3.1]nonane Nucleusfrom the Xisha Soft Coral Sinularia polydactyla. Ye F, Zhu ZD, Chen JS, Li J, Gu YC, Zhu WL, Li XW*and Guo YW*. Org Lett (2017)19: 4183-4186··············································································································· 6.579 

  45.    Phainanolide A, Highly Modified and Oxygenated Triterpenoid from Phyllanthus hainanensis. Fan YY, Gan LS, Liu HC, Li H, Xu CH, Zuo JP, Ding J* and Yue JM*. Org Lett (2017)19: 4580-4583······ 6.579 

  46.    The Landscape of Histone Modifications in a High-Fat Diet-Induced Obese (DIO) Mouse Model. Nie L, Shuai L, Zhu M, Liu P, Xie ZF, Jiang S, Jiang HW, Li J, Zhao Y, Li JY* and Tan MJ*.Mol Cell Proteomics (2017)16(7): 1324-1334································································································ 6.54 

  47.    Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. Yuan B, Ye N, Song SS, Wang YT, Song ZL, Chen HD, Chen CH, Huan XJ, Wang YQ, Su SY, Shen YY, Sun YM, Yang XY, Chen Y, Guo SY, Gan Y, Gao ZW, Chen XY, Ding J, He JX*, Zhang A* and Miao ZH*. Cancer Lett (2017)386: 47-56·········································· 6.375 

  48.    Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition. Sun DN, Liu HC, Dai XY, Zheng XL, Yan J, Wei RR, Fu XH, Huang M, Shen AJ, Huang X*, Ding J* and Geng MY*. Cancer Lett (2017)406: 105-115···································· 6.375 

  49.    The miR-491-3p/Sp3/ABCB1 axis attenuates multidrug resistance of hepatocellular carcinoma. Zhao Y, Qi XM, Chen J, Wei WX, Yu CZ, Yan H, Pu MF, Li Y, Miao LL, Li CZ* and Ren J*.Cancer Lett (2017)408: 102-112·················································································································· 6.375 

  50.    Fluorescent glycoprobes: a sweet addition for improved sensing. He XP, Zang Y, Tony D. James*, Li J*, Chen GR* and Xie J*.Chem Commun (2017)53: 82-90······················································ 6.319 

  51.    Graphene oxide-enhanced cytoskeleton imaging and mitosis tracking. Li QR, Jiao JB, Li LL, He XP*, Zang Y*, Tony D. James, Chen GR, Guo L* and Li J*.Chem Commun (2017)53: 3373-3376············· 6.319 

  52.    Supramolecular core–glycoshell polythiophene nanodots for targeted imaging and photodynamic therapy. Han HH, Wang CZ, Zang Y, Li J*, Tony D. James and He XP*.  Chem Commun (2017)53: 9793-9796 6.319 

  53.    Supramolecular assembly of fluorogenic glyco-dots from perylenediimide-based glycoclusters for targeted imaging of cancer cells. Liu Y, Ji DK, Dong L, Nicolas Galanos, Zang Y, Li J*, Sebastien Vidal* and He XP*. Chem Commun (2017)53: 11937-11940··································································· 6.319 

  54.     Chemical antagonism between photodynamic agents and chemotherapeutics: mechanism and avoidance. Meng QS, Meng J, Ran W, Su JH, Yang YG, Zhang PC* and Li YP* . Chem Commun (2017)53: 12438-12441·········································································· 6.319 

  55.    Discovery of Novel Disruptor of Silencing Telomeric 1?Like (DOT1L) Inhibitors using a Target-Specific Scoring Function for the (S)?Adenosyl?L?methionine (SAM)-Dependent Methyltransferase Family. Wang YL, Li LJ, Zhang BD, Xing J, Chen SJ, Wan W, Song YK, Jiang H, Jiang HL, Luo C* and Zheng MY*. J Med Chem (2017)60: 2026-2036··················································································· 6.259 

  56.    Development of the First Generation of Disulfide-Based Subtype-Selective and Potent Covalent Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors. Liu YF, Xie ZQ, Zhao D, Zhu J, Mao F, Xu S, Luo C, Geng MY, Huang M and Li J*. J Med Chem (2017)60: 2227-2244················································ 6.259 

  57.    Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections. Tan L, Tao YL, Wang T, Zou F, Zhang SH, Kou QH, Niu A, Chen Q, Chu WJ, Chen XY, Wang HD* and Yang YS*. J Med Chem (2017)60: 2669-2684········ 6.259 

  58.    6?OH-Phenanthroquinolizidine Alkaloid and Its Derivatives Exert Potent Anticancer Activity by Delaying S Phase Progression. Liu YX, Qing LH, Meng CS, Shi JJ, Yang Y, Wang ZW, Han GF, Wang Y, Ding J, Meng LH* and Wang QM*. J Med Chem (2017)60: 2764-2779············································ 6.259 

  59.    Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer. Zhu W, Chen H, Wang YL, Wang J, Peng X, Chen XJ, Gao YL, Li CP, He YL, Ai J, Geng MY, Zheng MY* and Liu H*. J Med Chem (2017)60: 6018-6035················································································· 6.259 

  60.    Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization. Mao RF, Shao JW, Zhu KK, Zhang YY, Ding H, Zhang CH, Shi Z, Jiang HL, Sun DQ*, Duan WH* and Luo C*. J Med Chem (2017)60: 6289-6304 6.259 

  61.    Novel Inhibitors of Staphyloxanthin Virulence Factor in Comparison with Linezolid and Vancomycin versus Methicillin-Resistant, Linezolid-Resistant, and Vancomycin-Intermediate Staphylococcus aureus Infections in Vivo. Ni S, Wei H, Li B, Chen F, Liu Y, Chen W, Xu Y, Qiu X, Li X, Lu Y, Liu W, Hu L, Lin D, Wang M, Zheng X, Mao F, Zhu J, Lan LF* and Li J*. J Med Chem (2017)60: 8145-8159··········· 6.259 

  62.    Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription. Liu G, Huang WJ, Wang J, Liu XH, Yang J, Zhang Y, Geng Y, Tan WF* and Zhang A*. J Med Chem (2017)60: 8218-8245··················································································· 6.259 

  63.    Development of Potent Type I Protein Arginine Methyltransferase (PRMT) Inhibitors of Leukemia Cell Proliferation. Wang C, Jiang H, Jin J, Xie YQ, Chen ZF, Zhang H, Lian FL, Liu YC, Zhang CH, Ding H, Chen SJ, Zhang NX, Zhang YY*, Jiang HL, Chen KX, Ye F*, Yao ZY* and Luo C*. J Med Chem (2017)60: 8888-8905·································································································· 6.259 

  64.     Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2. Liu QF, Huang FB, Yuan XJ, Wang K, Zou Y, Shen JH* and Xu YC*. J. Med. Chem. (2017)60(24): 10231-10244························································································ 6.259 

  65.    MiR-1254 suppresses HO-1 expression through seed region-dependent silencing and non-seed interaction with TFAP2A transcript to attenuate NSCLC growth. Pu MF, Li CG, Qi XM, Chen J, Wang YZ, Gao LL, Miao LL* and Ren J*. PLoS Genet (2017)13(7):1-25····························································· 6.1 

  66.    AMPK regulates anaphase central spindle length by phosphorylation of KIF4A. Li QR, Yan XM, Guo L*, Li J* and Zang Y*. J Mol Cell Biol (2017): 1-16··································································· 5.988 

  67.    First evidence of pyrrolizidine alkaloid N?oxide?induced hepatic sinusoidal obstruction syndrome in humans. Yang MB, Ruan JQ, Gao H, Xue JY, Ye Y, Fu PC, Wang JY and Lin G*. Arch Toxicol (2017) 91: 3913-3925·········································································································· 5.901 

  68.    Low, but not high, dose caffeine is a readily available probe for adenosine actions. Bertil B. Fredholm*, Yang JN and Wang YQ. Mol Aspects Med (2017)55: 20-25················································· 5.686 

  69.    Palladium-Catalyzed, Silver-Assisted Direct C-5–H Arylation of 3-Substituted 1,2,4-Oxadiazoles under Microwave Irradiation. Li S, Wan PH, Ai J, Sheng R*, Hu YZ* and Hu YH*. Adv Synth Catal (2017)359: 772-778·················································································································· 5.646 

  70.    Cp*Rh(III)-Catalyzed Directed C H Methylation and Arylation of Quinoline N-Oxides at the C-8 Position. Wang B, Li CP and Liu H*. Adv Synth Catal (2017)359: 3029-3034······································· 5.646 

  71.    A small-molecule inhibitor of NF-kB-inducing kinase (NIK) protects liver from toxin-induced inflammation, oxidative stress, and injury. Ren XM, Li XZ, Jia LN*, Chen DH, Hou H, Rui LY, Zhao YJ* and Chen Z*. FASEB J (2017)31(2): 711-718···················································································· 5.498 

  72.    In Situ Monitoring Intracellular Structural Change of Nanovehicles through Photoacoustic Signals Based on Phenylboronate-Linked RGD-Dextran/Purpurin 18 Conjugates. Cheng DB, Qi GB, Wang JQ, Cong Y, Liu FH, Yu HJ, Qiao ZY* and Wang H*. Biomacromolecules (2017)18: 1249-1258························ 5.246 

  73.    Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors. Yu MM, Gao ZW, Dai XJ, Gong H, Zhang LS, Chen XY, Zhong DF* and Sherwin K. B. Sy*. Clin Pharmacokinet (2017) 56: 65-76························ 5.216 

  74.    Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution. He JX, Wang M, Huan XJ, Chen CH, Song SS, Wang YQ, Liao XM, Tan C, He Q, Tong LJ, Wang YT, Li XH, Su Y, Shen YY, Sun YM, Yang XY, Chen Y, Gao ZW, Chen XY, Xiong B, Lu XL, Ding J, Yang CH* and Miao ZH*. Oncotarget (2017)8(3): 4156-4168·· 5.168 

  75.    Highly enantioselective Rh/chiral sulfur-olefincatalyzed arylation of alkyl-substituted non-benzofused cyclic N-sulfonyl ketimines. Liu MQ, Jiang T, Chen WW* and Xu MH*. Org Chem Front (2017)4: 2159-2162······················································································································ 4.955 

  76.    Catalytic and catalyst-free diboration of alkynes. Zhao F, Jia XW, Li PY, Zhao JW, Zhou Y, Wang J and Liu H*. Org Chem Front (2017)4: 2235-2255··································································· 4.955 

  77.    C?H Trifluoromethylation of 2?Substituted/Unsubstituted Aminonaphthoquinones at Room Temperature with Bench-Stable (CF3SO2)2Zn: Synthesis and Antiproliferative Evaluation. Li J, Zhang XF, Xiang HY, Tong LJ, Feng F, Xie H, Ding J and Yang CH*. J Org Chem (2017)82: 6795-6800··················· 4.849 

  78.    Difluorination of Furonaphthoquinones. Li J, Xue Y, Fan ZL, Ding CY* and Zhang A*. J Org Chem (2017)82: 7388-7393·································································································· 4.849 

  79.    Design, synthesis and pharmacological evaluation of 4,5-diarylisoxazols bearing amino acid residues within the 3-amido motif as potent heat shock protein 90 (Hsp90) inhibitors. Zhang C, Wang X, Liu HC, Zhang MM, Geng MY, Sun LP*, Shen AJ* and Zhang A*. ····················· Eur J Med Chem (2017)125: 315-326 4.519 

  80.    SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kd) inhibitors. Wei MM, Zhang X, Wang X, Song ZL, Ding J, Meng LH* and Zhang A*. ··· Eur J Med Chem (2017)125: 1156-1171································································································ 4.519 

  81.    Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors. Liu Y, Peng X, Guan XC, Lu D, Xi Y, Jin SY, Chen H, Zeng LM, Ai J*, Geng MY* and Hu YH*. Eur J Med Chem (2017)126: 122-132··································································································· 4.519 

  82.    Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors. Zhuang RX, Gao LX, Lv XQ, Xi JJ, Sheng L, Zhao YM, He RY, Hu XB, Shao YD, Pan XW, Liu SR, Huang WW, Zhou YB*, Li J* and Zhang JK*. Eur J Med Chem (2017)126: 1056-1070··· 4.519 

  83.    A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties. Yu L, Huang MH, Xu TF, Tong LJ, Yan XE, Zhang Z, Yong Xu a, CH Yun e, Xie H *, Ding K * and Lu XY * Eur J Med Chem (2017)126: 1107-1117···· 4.519 

  84.    The synthesis and antistaphylococcal activity of 9, 13-disubstituted berberine derivatives. Wang J, Yang T, Chen H, Xu YN, Y LF, Liu T, Tang J, Yi ZF, Yang CG, Xue W* and Yang F*. Eur J Med Chem (2017)127: 424-433··································································································· 4.519 

  85.    The synthesis and antistaphylococcal activity of dehydroabietic acid derivatives: modifications at C12 and C7. ZhangWM, Yang T, Pan XY, Liu XL, Lin HX, Gao ZB, Yang CG* and Cui YM*. Eur J Med Chem (2017)127: 917-927··································································································· 4.519 

  86.    Discovery, mechanism and metabolism studies of 2,3-difluorophenyllinker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy. Chen WH, Guo N, Qi MH, Dai HY, Hong MH, Guan LF, Huan XJ, Song SS, He JX, Wang YQ, Xi Y, Yang XY, Shen YY, Su Y, Sun YM, Gao YL, Chen Y, Ding J, Tang Y, Ren GB*, Miao ZH* and Li J*. Eur J Med Chem (2017)128: 514-531··············· 4.519 

  87.    Discovery of benzofuran-3(2H)-one derivatives as novel DRAK2 inhibitors that protect islet β-cells from apoptosis. Wang S, Xu L, Lu YT, Liu YF, Han B, Liu T, Tang J, Li J, Wu JP*, Li JY*, Yu LF*and Yang F*. Eur J Med Chem (2017)130: 195-208············································································· 4.519 

  88.    Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor. Hu JP, Wang YQ, Li YL, Xu L, Cao DY, Song SS, Mohammadali Soleimani Damaneh, Wang X, Meng T, Chen YL, Shen JK*, Miao ZH* and Xiong B*. Eur J Med Chem (2017)137: 176-195· 4.519 

  89.    Design, synthesis and biological evaluation of 4,7,12,12a-tetrahydro-5H-thieno[3',2:3,4]pyrido[1,2-b]isoquinolines as novel adenosine 5'-monophosphate-activated protein kinase (AMPK) indirect activators for the treatment of type 2 diabetes. Zhou SB, Duan YN, Wang J, Zhang J, Sun HF, Jiang HW, Gu ZN, Tong JH, Li JY, Li J * and Liu H*. Eur J Med Chem (2017)140: 448-464································ 4.519 

  90.    Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC. Chen LF, Fu WT, Feng C, Qu R, Tong LJ, Zheng LL, Fang B, Qiu YD, Hu J, Cai YP, Feng JP, Xie H, Ding J*, Liu ZG* and Liang G*. Eur J Med Chem (2017)140: 510-527···················· 4.519 

  91.    Critical Role of Hepatic Cyp450s in the Testis-Specific Toxicity of (5R)-5-Hydroxytriptolide in C57BL/6 Mice. Yu CZ, Li Y, Liu MX, Gao M, Li CG, Yan H, Li CZ, Sun LH, Mo LY, Wu CY, Qi XM* and Ren J. Front Pharmacol (2017): 00832······················································································· 4.4 

  92.    Arylacetamide deacetylase is involved in vicagrel bioactivation in humans. Jiang JF, Chen XY and Zhong DF*. Front Pharmacol (2017): 00846················································································ 4.4 

  93.    Tryptic Peptides Bearing C-Terminal Dimethyllysine Need to Be Considered during the Analysis of Lysine Dimethylation in Proteomic Study. Chen M, Zhang M, Zhai L, Hu H, Liu P and Tan MJ*. J Proteome Res (2017)1;16(9): 3460-3469···························································································· 4.268 

  94.    Structure-Guided Design of C4-alkyl-1,4-dihydro-2Hpyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors. Hao YJ, Lyu JK, Qu R, Sun DH, Zhao ZJ, Chen Z, Ding J, Xie H*, Xu YF* and Li HL*. Sci Rep (2017)7: 3830···· 4.2589 

  95.    New Bicyclic Cembranoids from the South China Sea Soft Coral Sarcophyton trocheliophorum. Liang LF, Chen WT, Li XW, Wang HY and Guo YW*. Sci Rep (2017)7: 46584···································· 4.2589 

  96.    Phospholipid-mimic oxaliplatin prodrug liposome for treatment of the metastatic triple negative breast cancer. Feng B, Zhou FY, Lu WC, Wang DG, Wang TT, Luo C, Wang H, Li YP and Yu HJ*. Biomater Sci (2017)5: 1522-1525····································································································· 4.21 

  97.    Targeting SPOP with small molecules provides a novel strategy for kidney cancer therapy. Zheng T and Yang CG*. Sci China (2017)60: 91-93············································································ 4.132 

  98.    Exploiting histone deacetylases for cancer therapy: from hematological malignancies to solid tumors. Huang M and Geng MY*. Sci China (2017)60: 94-97·································································· 4.132 

  99.    SIRT7 deacetylates DDB1 and suppresses the activity of the CRL4 E3 ligase complexes. Mo Y, Lin R, Liu P, Tan M, Xiong Y, Guan KL and Yuan HX*. FEBS J (2017)284(21): 3619-3636························· 3.902 

  100. Downregulation of lipin-1 induces insulin resistance by increasing intracellular ceramide accumulation in C2C12 myotubes. Huang SJ, Huang SL, Wang X, Zhang QL, Liu J and Leng Y*. Int J Biol Sci (2017)13: 1-12······················································································································· 3.873 

  101. Machine-Learning-Assisted Approach for Discovering Novel Inhibitors Targeting Bromodomain-Containing Protein 4. Xing J, Lu WC, Liu RF, Wang YL, Xie YQ, Zhang H, Shi Z, Jiang H, Liu YC, Chen KX, Jiang HL, Luo C* and Zheng MY*. J Chem Inf Model (2017)57: 1677-1690····································· 3.76 

  102. Design, Synthesis, and Biological Evaluation of the First c?Met/HDAC Inhibitors Based on Pyridazinone Derivatives. Lu D, Yan J, Wang L, Liu HC, Zeng LM, Zhang MM, Duan WW, Ji YC, Cao JC, Geng MY, Shen AJ* and Hu YH*. ACS Med Chem Lett (2017)8: 830-834············································· 3.746 

  103.   Discovery of a Novel Series of 7?Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity. Yang CB, Zhang X, Wang Y, Yang YT, Liu XF, Deng ML, Jia Y, Ling Y, Meng LH* and Zhou YM*. ACS Med Chem Lett (2017)8: 875-880············································································ 3.746 

  104. (5R)-5-Hydroxytriptolide ameliorates lupus nephritis in MRL/lpr mice by preventing infiltration of immune cells. Zhang LY, Li H, Wu YW, Cheng L, Yan YX, Yang XQ, Zhu FH, He SJ, Tang W* and Zuo JP*. Am J Physiol Renal Physiol (2017)1;312(4):F769-F777···························································· 3.611 

  105. Optimization and Synthesis of Pyridazinone Derivatives as Novel Inhibitors of Hepatitis B Virus by Inducing Genome-free Capsid Formation. Lu D, Liu FF, Xing WQ, Tong XK,Wang L, Wang YJ and Zeng LM, Feng CL, Yang L*, Zuo JP* and Hu YH*. ACS Infect Dis (2017)3: 199-205·························· 3.6 

  106. Recent advances in rhodium-catalyzed asymmetric synthesis of heterocycles. Chen WW and Xu MH*. Org Biomol Chem (2017)15: 1029-1050··············································································· 3.564 

  107. Discovery and optimization of selective inhibitors of protein arginine methyltransferase 5 by docking-based virtual screening. Ye Y, Zhang BD, Mao RF, Zhang CH, Wang YL, Xing J, Liu YC, Luo XM, Ding H, Yang YX, Zhou B, Jiang HL, Chen KX, Luo C* and Zheng MY*. Org Biomol Chem (2017)15: 3648-3661······ 3.564 

  108. Rhodium-catalyzed redox-neutral coupling of phenidones with alkynes. Fan ZL, Lu H, Li W, Geng KJ and Zhang A*. Org Biomol Chem (2017)15: 5701-5708··························································· 3.564 

  109. Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues. Jiang H, Xing J, Wang C, Zhang H, Yue LY, Wan XZ, Chen W, Ding H, Xie YQ, Tao HR, Chen ZF, Jiang HL, Chen KX, Chen SJ*, Zheng MY*, Zhang YY* and Luo C. Org Biomol Chem (2017)15: 9352-9361··········· 3.564 

  110. Recent Advances in the Isolation, Synthesis and Biological Activity of Marine Guanidine Alkaloids. Liu J, Li XW* and Guo YW*. Mar Drugs (2017)15: 324······························································ 3.503 

  111. Structural diversity, biological properties and applications of natural products from Cyanobacteria. A Review.  S. A.Ali Shah, N. Akhter, B. N. Auckloo, I. Khan, Lu YB, Wang KW, Wu B* and Guo YW*. Mar Drugs (2017)15: 354·································································································· 3.503 

  112. D-A-D fluorogenic probe for the rapid imaging of amyloid b plaques in vivo. Yang HY, Zhang JJ, Zang Y, Zhang HY*, Li J*, Chen GR and He XP*.Dyes Pigments (2017)136: 224-228·························· 3.473 

  113. Label-free brainwide visualization of senile plaque using cryo-micro-optical sectioning tomography. Luo Y, Wang A, Liu M, Lei T, Zhang X, Gao Z, Jiang H, Gong H and Yuan J*. Opt Lett (2017)42(21): 4247-4250 3.416 

  114. Naturally occurring furanoditerpenoids: distribution, chemistry and their pharmacological activities. Bao H, Zhang QW, Ye Y and Lin LG*. Phytochem Rev (2017)16:235-270········································ 3.393 

  115. Nanomolar Antimalarial Agents against Chloroquine-Resistant Plasmodium falciparum from Medicinal Plants and Their Structure?Activity Relationships. Zhou B, Wu Y, Seema Dalal, Emilio F. Merino, Liu QF, Xu CH, Yuan T, Ding J, David G. I. Kingston, Maria B. Cassera and Yue JM*. J Nat Prod (2017)80: 96-107························································································································· 3.281 

  116. Crassins A?H, Diterpenoids from the Roots of Croton crassifolius. Yuan QQ, Tang S, Song WB, Wang WQ, Huang M and Xuan LJ*. J Nat Prod (2017)80: 254-260··············································· 3.281 

  117. Diterpenoids and Lignans from Cephalotaxus fortune. Zhao JX, Fan YY, Xu JB, Gan LS, Xu CH, Ding J and Yue JM*. J Nat Prod (2017)80: 356-362··································································· 3.281 

  118. Identification of Cyclic Depsipeptides and Their Dedicated Synthetase from Hapsidospora irregularis. Zhang SW, Qiu YX, Thomas B. Kakule, Lu ZY, Xu FC, John G. Lamb, Christopher A. Reilly, Zheng Y, Shing Wo Simon Sham, Wang W, Xuan LJ, Eric W. Schmidt and Zhan JX*. J Nat Prod (2017)80: 363-370························································································································ 3.281 

  119. Absolute Configuration of Periplosides C and F and Isolation of Minor Spiro-orthoester Group-Containing Pregnane-type Steroidal Glycosides from Periploca sepium and Their T?Lymphocyte Proliferation Inhibitory Activities. Wang LY, Qin JJ, Chen ZH, Zhou Y, Tang W, Zuo JP* and Zhao WM*. J Nat Prod (2017)80: 1102-1109··············································································································· 3.281 

  120. Marine Terpenoid Diacylguanidines: Structure, Synthesis, and Biological Evaluation of Naturally Occurring Actinofide and Synthetic Analogues. Marianna Carbone, M. Letizia Ciavatta, Ve?ronique Mathieu, Aude Ingels, Robert Kiss, Paola Pascale, Ernesto Mollo, Nicon Ungur, Guo YW* and Margherita Gavagnin*. J Nat Prod (2017)80: 1339-1346··················································································· 3.281 

  121. Cucurbitane Glucosides from the Crude Extract of Siraitia grosvenorii with Moderate Effects on PGC-1α Promoter Activity. Niu B, Ke CQ, Li BH, Li YY, Yi YJ, Luo YW, Shuai L, Yao S, Lin LG, Li J and Ye Y*. J Nat Prod (2017)80: 1428-1435····················································································· 3.281 

  122. Camellianols A?G, Barrigenol-like Triterpenoids with PTP1B Inhibitory Effects from the Endangered Ornamental Plant Camellia crapnelliana. Xiong J, Wan J, Ding J*, Wang PP, Ma GL, Li J and Hu JF*. J Nat Prod (2017)80: 2874-2882····················································································· 3.281 

  123. Ruthenium(II)-Catalyzed Redox-Neutral [3+2] Annulation of Indoles with Internal Alkynes via C?H Bond Activation: Accessing a Pyrroloindolone Scaffold. Xie YN, Wu XW, Li CP, Wang J, Li J* and Liu H*. J Nat Prod (2017)82: 5263-5273····················································································· 3.281 

  124. Orally Administrated Small Molecule Drugs with Intestine Targeted Profile: Recent Development and Prospects. Cao H, Wang K, Ye YL and Shen JH*. Curr Med Chem (2017)24: 3921-3937············ 3.249 

  125. CHARMM-GUI 10 Years for Biomolecular Modeling and Simulation. Sunhwan Jo, Cheng X, Jumin Lee, Seonghoon Kim, Sang-Jun Park, Dhilon S. Patel, Andrew H. Beaven, Kyu Il Lee, Huan Rui, Soohyung Park, Hui Sun Lee, Beno^t Roux, Alexander D. MacKerell, Jr, Jeffrey B. Klauda, Qi YF and Wonpil Im*. J Comput Chem (2017)38: 1114-1124······································································ 3.229 

  126. Smart nanoparticles improve therapy for drugresistant tumors by overcoming pathophysiological barriers. Liu JP, Wang TT, Wang DG, Dong AJ*, Li YP and Yu HJ*. Acta Pharmacol Sin (2017)38: 1-8··· 3.223 

  127. MicroRNA-1304 suppresses human non-small cell lung cancer cell growth in vitro by targeting heme oxygenase-1.Li CG, Pu MF, Li CZ, Gao M, Liu MX , Yu CZ, Yan H, Peng C, Zhao Y, Li Y, Ma ZL, Qi XM, Wang YZ, Miao LL* and Ren J*. Acta Pharmacol Sin (2017)38: 110-119······························· 3.223 

  128. Dual anti-ischemic effects of rosmarinic acid n-butyl ester via alleviation of DAPK-p53-mediated neuronal damage and microglial inflammation. Wu L, Feng HM, Zhao WM* and Zhang HY*. Acta Pharmacol Sin (2017)38: 459-468····································································································· 3.223 

  129. Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration. Sun JY, Wang JD, Wang X, Liu HC, Zhang MM, Liu YC, Zhang CH, Su Y, Shen YY, Guo YW*, Shen AJ* and Geng MY*. Acta Pharmacol Sin (2017)38: 551-560············ 3.223 

  130. 1,2:5,6-dianhydrogalactitol inhibits human glioma cell growth in vivo and in vitro by arresting the cell cycle at G2/M phase. Peng C, Qi XM, Miao LL* and Ren J*. Acta Pharmacol Sin (2017)38: 561-570···· 3.223 

  131. Dicer1/miR-29/HMGCR axis contributes to hepatic free cholesterol accumulation in mouse nonalcoholic steatohepatitis. Liu MX, Gao M, Li CZ, Yu CZ, Yan H, Peng C, Li Y, Li CG, Ma ZL, Zhao Y, Pu MF, Miao LL, Qi XM* and Ren J*. Acta Pharmacol Sin (2017)38: 660-671··········································· 3.223 

  132. Treating breast cancer metastasis with cabazitaxelloaded polymeric micelles. Zhong T, He B, Cao HQ, Tan T, Hu HY, Li YP and Zhang ZW*. Acta Pharmacol Sin (2017)38: 924-930······························ 3.223 

  133. Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors. Yang ZM, Liao XM, Chen Y, Shen YY, Yang XY, Su Y, Sun YM, Gao YL, Ding J, Zhang A, He JX* and Miao ZH*. Acta Pharmacol Sin (2017)38: 1038-1047····························· 3.223 

  134. Discovery of potent 2,4-difluoro-linker poly(ADPribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy. Chen WH, Song SS, Qi MH, Huan XJ, Wang YQ, Jiang HL, Ding J, Ren GB*, Miao ZH* and Li J*. Acta Pharmacol Sin (2017)38: 1521-1532····················· 3.223 

  135. Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer. Xie Q, Chen H, Ai J, Gao YL, Geng MY, Ding J* and Chen Y*. Acta Pharmacol Sin (2017)38: 1533-1542·································································································· 3.223 

  136. Hypoxia induces universal but differential drug resistance and impairs anticancer mechanisms of 5-fluorouracil in hepatoma cells. Li JQ, Wu X, Gan L, Yang XL* and Miao ZH*. Acta Pharmacol Sin (2017)38: 1642-1654·································································································· 3.223 

  137. Conformation and dynamics of the C-terminal region in human phosphoglycerate mutase 1. Liu SE, Hu JC, Zhang H, Xu P, Wan W, Zheng MY, Yu KQ, Ding H, Jiang HL, Zhou L* and Luo C*. Acta Pharmacol Sin (2017)38: 1673-1682·································································································· 3.223 

  138. Discovery of a novel calcium-sensitive fluorescent probe for α-ketoglutarate. Gan LL, Chen LH and Nan FJ*. Acta Pharmacol Sin (2017)38: 1683-1690································································· 3.223 

  139. Compositacins AeK: Bioactive chamigrane-type halosesquiterpenoids from the red alga Laurencia composita Yamada. Yu XQ, Jiang CS, Zhang Y, Sun P, Tibor Kurt an, Attila M, Li XL, Yao LG, Liu AH, Wang B, Guo YW and Mao SC*. Phytochemistry (2017)136: 81-93······································· 3.205 

  140. Deheiculatins A-L, 20-oxygenated cembranoids from Macaranga deheiculata. Qi WY, Shen Y, Wu Y, Leng Y, Gao K* and Yue JM*. Phytochemistry (2017)136: 101-107······································· 3.205 

  141. Recent approaches for asymmetric synthesis of α?amino acids via homologation of Ni(II) complexes. Wang YB, Song XH, Wang J, Hiroki Moriwaki, Vadim A. Soloshonok and Liu H*. Amino Acids (2017)49: 1487-1520······················································································································ 3.173 

  142. Structural and Stereochemical Studies of Laurokamurols A?C, Uncommon Bis-sesquiterpenoids from the Chinese Red Alga Laurencia okamurai Yamada. Li XL, T. Kurtán, Hu JC, A. Mándi, Li J, Li XW* and Guo YW*. J Agric Food Chem (2017)65: 1550-1555································································ 3.154 

  143. Dicarabrol A, dicarabrone C and dipulchellin A, unique sesquiterpene lactone dimers from Carpesium abrotanoides. Wu JW, Tang CP, Ke CQ, Yao S, Liu HC, Lin LG* and Ye Y*. RSC Adv (2017)7: 4639-4644······················································································································ 3.108 

  144. Global and untargeted metabolomics evidence of the protective effect of different extracts of Dipsacus asper Wall. ex C.B. Clarke on estrogen deficiency after ovariectomia in rats. Tao Y*, Chen X, Li WD, Cai BC, Di LQ, Shi LY and Hu LH. J Ethnopharmacol (2017)199: 20-29······································ 2.981 

  145. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes. Kenneth K.W. To, Wu X, Yin C Stella Chai, Yao S, Onat Kadioglue, Thomas Efferth, Ye Y* and Lin G*. J Ethnopharmacol (2017)203: 110-119·················································· 2.981 

  146. Design and optimization of purine derivatives as in vivo active PDE10A inhibitors. Chen L, Chen DQ, Tang L, Ren J, Chen JJ, Zhen XC, Liu YC, Zhang CH, Luo HB, Shen JK* and Xiong B*. Bioorgan Med Chem (2017)25: 3315-3329··························································································· 2.93 

  147. Discovery of a low-systemic-exposure DGAT-1 inhibitor with a picolinoylpyrrolidine-2-carboxylic acid moiety. Yan JW, Wang GH, Dang XY, Guo BB, Chen WH, Wang T, Zeng LM, Wang HY and Hu YH*. Bioorgan Med Chem (2017)25: 4701-4714········································································ 2.93 

  148. Phosphoglycerate Mutase 1 Predicts the Poor Prognosis of Oral Squamous Cell Carcinoma and is Associated with Cell Migration. Zhang DD, Wu HM, Zhang XM, Ding X, Huang M, Geng MY, Li HW* and Xie ZQ*. J Cancer (2017)5;8(11): 1943-1951·················································································· 2.916 

  149. Discovery and Biological Evaluation of a Series of Pyrrolo[2,3-b]pyrazines as Novel FGFR Inhibitors. Zhang Y, Liu HC, Zhang Z, Wang RF, Liu TC, Wang CY, Ma YC*, Ai J, Zhao DM, Shen JK and Xiong B*. Molecules (2017)22: 583························································································ 2.861 

  150. Design, Synthesis and Anti-Proliferative Activities of 2,6-Substituted Thieno[3,2-d]pyrimidine Derivatives Containing ElectrophilicWarheads. Zhang QM, Hu ZL, Shen QQ, Chen Y* and Lu W*. Molecules (2017)22: 788··········································································································· 2.861 

  151. Bioequivalence of generic alendronate sodium tablets (70 mg) to Fosamax tablets (70 mg) in fasting, healthy volunteers: a randomized, open-label, three-way, reference-replicated crossover study. Zhang YF, Chen XY, Tang YB, Lu YM, Guo LX and Zhong DF*. Drug Des Dev Ther (2017)11: 2109-2119·· 2.822 

  152. The development of small-molecule modulators for ClpP protease activity. Ye F, Li JH and Yang CG*. Mol BioSyst (2017)13: 23-31······························································································ 2.781 

  153. Targeting sphingosine-1-phosphate signaling for cancer therapy. Xie Z, Liu H* and Geng MY*. Sci China Life (2017)60(6): 585-600··························································································· 2.781 

  154. New monoterpenoid oxindole alkaloid derivatives from the stems of Uncaria hirsuta Havil. and their cytotoxicity and tandem mass spectrometric fragmentation. Pan HQ, Yang WZ, Zhao D, Luo C, Yao CL, Shi XJ, Zhang YB, Li SY, Bi Y, ZW, Yao S, Wu WY* and Guo DA*. Fitoterapia (2017)116: 85-92 2.698 

  155. Scubatines A–F, new cytotoxic neo-clerodane diterpenoids from Scutellaria barbata D. Don. Yuan QQ, Song WB, Wang WQ and Xuan LJ*. Fitoterapia (2017)119: 40-44······································· 2.698 

  156. Isoprenylated phenolic compounds with PTP1B inhibition from Morus alba. Huang QH, Lei C, Wang PP, Li JY, Li J and Hou AJ*. Fitoterapia (2017)122: 138-143···················································· 2.698 

  157. Pd(II)-catalyzed cascade Heck/intramolecular C(sp2)eH amidation reaction: An efficient route to 4-aryl-2-quinolinones. Xiao CQ, Wang ZY, Lei M* and Hu LH*. Tetrahedron (2017)73: 204-211············· 2.651 

  158. Stereoselective addition of Grignard reagents to (2-methyl-5-tertbutyl) phenyl 1-thio-β-D-ribopentodialdo-1,4-furanoside derivative. Ren HM, Xie WC, Xiong B, Shen JK, Chen GH* and Chen YL*. Tetrahedron (2017)73: 2290-2304·································································································· 2.651 

  159. Two new lignan-iridoid glucoside diesters from the leaves of Vaccinium bracteatum and their relative and absolute configuration determination by DFT NMR and TDDFT-ECD calculation. Ren YM, Ke CQ, Attila M andi, Tibor Kurt an, Tang CP, Yao S and Ye Y*.Tetrahedron (2017)73: 3213-3219···················· 2.651 

  160. Natural occurrence of all eight stereoisomers of a neosecurinane structure from Flueggea virosa. Zhang H, Zhu KK, Gao XH and Yue JM*. Tetrahedron (2017)73: 4692-4697······································· 2.651 

  161. Axiriabilines A-D, uncommon nitrogenous eudesmane-type sesquiterpenes from the Hainan sponge Axinyssa variabilis. Li XW, Chen SH, Ye F, Ernesto Mollo, Zhu WL, Liu HL and Guo YW*. Tetrahedron (2017)73: 5239-5243·································································································· 2.651 

  162. The Second-generation of Highly Potent Hepatitis C Virus (HCV) NS3/4A Protease Inhibitors: Evolutionary Design Based on Tailor-made Amino Acids, Synthesis and Major Features of Bio-activity. Wang SN, Wang YB, Wang J, Tatsunori Satod, Kunisuke Izawa*, Vadim A. Soloshonok* and Liu H*. Current Pharm Design (2017)23: 1-62································································································ 2.611 

  163. Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells. Luo LX, Fan XX, Li Y, Peng X, Ji YC, Wendy Wen-Luan Hsiao, Liu L*, Elaine Lai-Han Leung* and Yao XJ*. MedChemCommun (2017)8: 621-624········································································ 2.608 

  164. Discovery of novel trimethoxy-ring BRD4 bromodomain inhibitors: AlphaScreen assay, crystallography and cell-based assay. Chen ZF, Zhang H, Liu SE, Xie YQ, Jiang H, Lu WC, Xu H, Yue LY, Zhang YY*, Ding H*, Zheng MY, Yu KQ, Chen KX, Jiang HL and Luo C*. MedChemCommun (2017)8: 1322-1331· 2.608 

  165. Simultaneous determination of eight Danshen polyphenols in rat plasma and its application to a comparative pharmacokinetic study of DanHong injection and Danshen injection. Li XX, Du FF, Jia WW, Olajide E. Olaleye, Xu F, Wang FQ and Li L*. J Sep Sci (2017)40: 1470-1481······································· 2.557 

  166. Salvia miltiorrhiza Roots against Cardiovascular Disease: Consideration of Herb-Drug Interactions. Chen F, Li L and Tian DD*. Biomed Res Int (2017): 9868694··························································· 2.476 

  167. Discovery of novel DNA methyltransferase 3A inhibitors via structurebased virtual screening and biological assays. Shao ZY, Xu P, Xu W, Li LJ, Liu SE, Zhang RK, Liu YC, Zhang CH, Chen SJ* and Luo C*. Bioorg Med Chem Lett (2017)27: 342-346······································································· 2.454 

  168.   Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays 

  Sun ZY, Zhang H, Chen ZF, Xie YQ, Jiang H, Chen LM*, Ding H*, Zhang YY, Jiang HL, Zheng MY and Luo C* 

  ······· Bioorg Med Chem Lett (2017)27: 2003-2009···································································· 2.454 

  169. Synthesis and structure–activity relationship study of pyrazolo[3,4-d]pyrimidines as tyrosine kinase RET inhibitors. Wang CY, Liu HC, Song ZL, Ji YC, Xing L, Peng X, Wang XS*, Ai J*, Geng MY and Zhang A*. Bioorg Med Chem Lett (2017)27: 2544-2548······························································· 2.454 

  170. Preparation of 5'-deoxy-5'-amino-5'-C-methyl adenosine derivatives and their activity against DOT1L. Liu TC, Xie WC, Li C, Ren HM, Mao YD, Chen GH, Cheng MS, Zhao DM, Shen JK, Li J, Zhou YB*, Xiong B* and Chen YL*. Bioorg Med Chem Lett (2017)27: 4960-4963··········································· 2.454 

  171. Benzo[c][1,2,5]thiadiazole derivatives: A new class of potent Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors. Wang WL, Chen XY, Gao Y, Gao LX, Sheng L, Zhu JY, Xu L, Ding ZZ, Zhang C, Li JY, Li J and Zhou YB*. Bioorg Med Chem Lett (2017)27: 5154-5157········· 2.454 

  172. Solvent-accessibility of discrete residue positions in the polypeptide hormone glucagon by 19F-NMR observation of 4-fluorophenylalanine. Hou YG, Hu WH, Li XN, John J. Skinner, Liu DS and Kurt Wüthrich*. J Biomol NMR (2017)68: 1-6·············································································· 2.41 

  173. Design and synthesis of Atglistatin derivatives as adipose triglyceride lipase inhibitors. Jin J, Huang S, Wang L, Leng Y* and Lu W*. Chem Biol Drug Des (2017)90(6): 1122-1133···························· 2.396 

  174. Isolation and Structure Characterization of Cytotoxic Phorbol Esters from the Seeds of Croton tiglium. Du QZ, Zhao YC, Liu HC, Tang CP, Zhang MM, Ke CQ and Ye Y*. Planta Med (2017)83: 1361-1367 2.342 

  175. Pharmacokinetics, safety, and tolerability of sulcardine sulfate: an open-label, single-dose, randomized study in healthy Chinese subjects. Chen Q, Qian HJ, Wang W, Zhang MQ, Lu DY, Lu C, Jin JM, Hu CY, Liu GY, Jia JY, Zheng HC, Li XN, Yu C, Wang YP and Liu Y*. Fund Clin Pharmacol (2017)31: 120-125 2.319 

  176. Detecting drug-induced changes in ECG parameters using jacketed telemetry: Effect of different data reduction techniques. Matthew Skinner*, Xing GZ, Lu J, Ren J and Karen Oldman. J Pharmacol Toxicol (2017)85: 38-48········································································································ 2.238 

  177. Two new dimmeric xanthanolides isolated from Xanthium mogolium Kitag plant. Xu FW, Xiao CQ, Lv X, Lei M and Hu LH*. Tetrahedron Lett (2017)58: 1312-1315·················································· 2.193 

  178. Divaccinosides A–D, four rare iridoid glucosidic truxillate esters from the leaves of Vaccinium bracteatum. Ren YM, Ke CQ, Tang CP, Yao S and Ye Y*. Tetrahedron Lett (2017)58: 2385-2388················ 2.193 

  179. An efficient synthesis of the 1,6-dioxaspiro[4.4]nonan-2-one motif of the immunosuppressive triterpenoid Phainanoid F. Zhang CL and Nan FJ*. Tetrahedron Lett (2017)58: 4357-4359·························· 2.193 

  180. Corroborating study on the absolute configurations of trigochinins A–C. Fan YY, Chen SX, Liu QF, Gan LS* and Yue JM*. Tetrahedron Lett (2017)58: 4728-4730··················································· 2.193 

  181. Chiral Phosphorus-Olefin Ligands for Asymmetric Catalysis. Yu YN and Xu MH*. Acta Chim Sinica (2017)75: 655-670······································································································ 2.131 

  182. Discovery of Bisindole as a Novel Scaffold for Protein Tyrosine Phosphatase 1B Inhibitors. Jing CC, Li ZY, Jia KL, Chen C, Liu X, Wang BB, Hu WH, Li J, Zhu T* and Dong SZ. Arch Pharm Chem Life Sci (2017)350: e1600173································································································· 1.994 

  183. Cyanobacterial peptides as a prototype for the design of cathepsin D inhibitors . Xu H, Bao KT, Tang S, Ai J*, Hu HY* and Zhang W*. J Pept Sci (2017)23: 701-706··················································· 1.972 

  184. Clavirolide G, a new rare dolabellane-type diterpenoid from the Xisha soft coral Clavularia viridis. Gao Y, Xiao W, Liu HC, Wang JR, Yao LG, Wang DC and Guo YW* . Chinese Chem Lett (2017)28: 905-908··· 1.932 

  185. Cytotoxic germacrane-type sesquiterpene lactones from the whole plant of Inula cappa. Wu JW, Tang CP, Cai YY, Ke CQ, Lin LG, Yao S* and Ye Y* Chinese Chem Lett (2017)28: 927-930···················· 1.932 

  186. 5-Alkylpyrrole-2-carboxaldehyde derivatives from the Chinese sponge Mycale lissochela and their PTP1B inhibitory activities. Xue DQ, Liu HL, Chen SH, Ernesto Mollo, Margherita Gavagnin, Li J, Li XW* and Guo YW*. Chinese Chem Lett (2017)28: 1190-1193··························································· 1.932 

  187. Three new dimeric diterpenes from Rhododendron molle. Zhou SZ, Tang CP, Ke CQ, Yao S, Lin G and Ye Y*. Chinese Chem Lett (2017)28: 1205-1209································································ 1.932 

  188. Cytotoxic cassane diterpenoids from the seeds of Caesalpinia sappan. Wu ZF, Bao H, Zhou FY, Liu JX, Meng FC, Feng L, Lu JJ, Zhang QW, Ye Y and Lin LG*. Chinese Chem Lett (2017)28: 1711-1715 1.932 

  189. Synthetic Analogues of Betulinic Acid as Potent Inhibitors of PS1/BACE1 Interaction to Reduce Aβ Generation. Zhang CL, Wang XY, Cui J, Li XH, Zhang YM, Wang X, Gu HF, Li W, Xie X, Zhao J, Pei G and Nan FJ*. Chin J Chem (2017)35: 103-112································································· 1.852 

  190. A Novel sarsolenane diterpene as a PTP1B Inhibitor from Hainan soft coral Sarcophyton trocheliophorum Marenzeller. Liang LF, Wang JA, Shi XX, Zhu YH, Li J, Zhu WL, Wang HY and Guo YW*. Chin J Chem (2017)35: 1246-1250·································································································· 1.852 

  191. Asymmetric Synthesis of Chiral Trifluoromethyl Containing Heterocyclic Amino Acids. Zhao L, Zhou SB, Tong JH, Wang J* and Liu H*. Chin J Chem (2017)35: 1540-1548······································· 1.852 

  192.   A new patchoulane-type sesquiterpenoid glycoside from the roots of Croton crassifolius. Yuan QQ, Song WB, Wang WQ and Xuan LJ*. Nat Prod Res (2017)31: 289-293··················································································· 1.828 

  193. Characterizing the interactions of two lipid modifications with lipid rafts: farnesyl anchors vs. palmitoyl anchors. Zhang T, Luo QC, Yang LL, Jiang HL* and Yang HY*. Eur Biophys J (2017): 1-12········ 1.472 

  194. Sarcophytrols G - L, novel minor metabolic components from South China Sea soft coral Sarcophyton trocheliophorum MARENZELLER. Liang LF, Chen WT, Li XW, Wang HY and Guo YW*. Chem Biodiv (2017)14: 6··············································································································· 1.44 

  195. Cytotoxic sesquiterpene lactones from Artemisia anomala. Li L, Liu HC, Tang CP, Yao S, Ke CQ, Xu CH and Ye Y*. Phytochem Lett (2017)20: 177-180·································································· 1.418 

  196. New ent-kaurane and ent-pimarane diterpenoids from Siegesbeckia pubescens. Yuan QQ, Song WB, Wang WQ, Wei JJ, Li J, Liu Y and Xuan LJ*. Phytochem Lett (2017)21: 273-277······························ 1.418 

  197. Diterpenoids from the needles and twigs of the cultivated endangered pine Pinus kwangtungensis and their PTP1B inhibitory effects. Hu CL, Xiong J*, Wang PP, Ma GL, Tang Y, Yang GX, Li J and Hu JF*. Phytochem Lett (2017)20: 239-245················································································ 1.418 

  198.                                                                                                                                                                                                                     Oral bioavailability and mass balance studies of a novel anti-arrhythmic agent Sulcardine sulfate in Sprague-Dawley rats and Beagle dogs. Lu YL, Li SJ, Liu GY, Li XC, Yang D, Jia JY, Zhang MQ, Zheng HC, Yu C, Zhu F and Wang YP* 

  ······· Eur J Drug Metab Pharmacokinet (2017)42(3): 453-459························································ 1.4 

  199. Multiple Dose Pharmacokinetics and Safety of Sulcardine Sulfate in Healthy Chinese Subjects: An Open-Label Phase I Clinical Study. Wang W, Qian HJ, Xin L, Zhang MQ, Lu DY, Jin JM, Liu GY, Jia JY, Zheng HC, Yu C, Wang YP, Zhu F* and Liu Y*. ········· Eur J Drug Metab Pharmacokinet (2017)42(4): 593-599 1.4 

  200. A one-pot synthesis of omarigliptin and its analogues through stabilized beta-amino ketone intermediate. Li Y, Liu TC, Li CG, Xiong B, Zhao DM, Cheng MS, Chen GH, Shen JK and Chen YL*. Synthetic Commun (2017)47(4): 357-363································································································· 1.134 

  201. Aglaiabbrevins A–D, New Prenylated Bibenzyls from the Leaves of Aglaia abbreviata with Potent PTP1B Inhibitory Activity. Sun P, Jiang CS, Zhang Y, Liu AH, Liang TJ, Li J, Guo YW, Jiang JM, Mao SC* and Wang B*. Chem Pharm Bull (2017)65: 295-299······························································· 1.133 

  202. Two pairs of rare naturally occurring 4-hydroxy-4-methyl-2,5-heptanedione derivatives from the red alga Chondria crassicaulis. Tong L, Zhang Y, Liu AH, Yao LG, Guo YW, Mao SC* and Wang B*. J Asian Nat Prod Res (2017)6: 572-580·························································································· 1.071 

  203. Further brominated polyacetylenes with pancreatic lipase inhibitory activity from Chinese marine sponge Xestospongia testudinaria. Yang M, Liang LF, Wang T, Wang HY*, Liu HL and Guo YW*. J Asian Nat Prod Res (2017)7: 732-737·························································································· 1.071 

  204. Concise synthesis and PTP1B inhibitory activity of (R)- and (S)-dihydroresorcylide. Jiang CS, Zhang L, Gong JX, Li JY, Yao LG, Li J and Guo YW*. J Asian Nat Prod Res (2017)19: 1204-1213··········· 1.071 

  205.                                                                                                                                                                                                                     A Clavuridins A and B, two new trinor-guaiane sesquiterpenes from the Xisha soft coral Clavularia viridis. Gao Y, Xiao W, Liu HC, Wang JR, Ouyang PK, Yao LG, Wang DC and Guo YW*. Chin J Nat Med (2017)15(11) 0855-0859···························································································· 1.047 

  206. Synthesis and activity evaluation of novel 3,4-dihydro-1-benzo[b]-oxepin-5(2H)-one derivatives as protein kinases inhibitors. Hou GG, Jiang CS, Liu HC, Tong LJ, Peng X, Ji YC, Geng MY, Xiao W*, Gong JX* and Guo YW. Chinese J Org Chem (2017)37: 1463-1472······················································ 1.01 

  207. Transition Metal-Catalyzed Asymmetric Addition of Organoboron Reagents to Imines. Chen D and Xu MH*. Chinese J Org Chem (2017)37: 1589-1612································································ 1.01 

  208. Isocartormin,anovelquinochalcone C-glycoside from Carthamus tinctorius. Li F, He ZS and Ye Y*. Acta Pharm Sin B (2017)7(4): 527-531··························································································  

  209. TRPA1 channel mediates organophosphate-induced delayed neuropathy. Ding Q, Fang S, Chen XQ, Wang YX, Li J, Tian FY, Xu X, Bernard Attali, Xie X and Gao ZB*. Cell Discov (2017)3: 17024·····················  

  210. Chemical Constituents from Mycelia and Spores of Fungus Cordyceps cicadae. Wang JH, Zhang ZL, Wang YQ, Yang M, Wang CH*, Li XW* and Guo YW. Chinese Herbal Medicine (2017)9: 188-192················  

  211. 中药多成分药代动力学研究:思路与方法. 李川. 中国中药杂志(2017)42(4): 607-617······················  

  212. Total Syntheses of Naucleamides A?C and E, Geissoschizine, Geissoschizol, (E)?Isositsirikine, and 16-epi-(E)?Isositsirikine. Li L, Paruke Aibibula, Jia QL and Jia YX*. Org Lett (2017)19: 2642-2645········· 6.579 

  213. Total Syntheses of Festuclavine, Pyroclavine, Costaclavine, epi-Costaclavine, Pibocin A, 9?Deacetoxyfumigaclavine C, Fumigaclavine G, and Dihydrosetoclavine. Liu HC, Zhang XW, Shan D, Mallesham Pitchakuntla, Ma YF and Jia YX*. Org Lett (2017)19: 3323-3326··························· 6.579 

  214. One-pot Synthesis of 6-Azachromone Derivatives Through Cascade Carbonylation-Sonogashira-Cyclization. Cheng G, Qi YB, Zhou XQ, Sheng R*, Hu YZ* and Hu YH. Sci Rep (2017)7: 4398· 4.2589 

  215. Ginsenoside Rb2 Alleviates Hepatic Lipid Accumulation by Restoring Autophagy via Induction of Sirt1 and Activation of AMPK. Huang Q, Wang T, Yang L and Wang HY*. Int J Mol Sci (2017)18: 1063···· 3.226 

  216. Delivery of acetylthevetin B, an antitumor cardiac glycoside, using polymeric micelles for enhanced therapeutic efficacy against lung cancer cells. Zhu JJ, Zhang XX*, Miao YQ, He SF, Tian DM, Yao XS, Tang JS* and Gan Y*. Acta Pharmacol Sin (2017)38: 290-300············································ 3.223 

  217. The Spatio-Temporal Expression Profiles of CD4+ T Cell Differentiation and Function-Related Genes During EAE Pathogenesis. Cai YY, Shen H, Qin CY, Zhou JF, Lai WM, Pan JP and Du CS*. Inflammation (2017)40: 195-204··················································································· 2.955 

  218. LLDT-288, a novel triptolide analogue exhibits potent antitumor activity in vitro and in vivo.Xu HT, Fan XT, Zhang GJ, Liu XY, Li ZH, Li YC* and Jiang B*.Biomed Pharmacother (2017)93: 1004-1009· 2.759 

  219. Identification of a diverse synthetic abietane diterpenoid library for anticancer activity. Xu HT, Liu LL, Fan XT, Zhang GJ, Li YC and Jiang B*.Bioorg Med Chem Lett (2017)27: 505-510························· 2.454 

  220.   Discovery of core-structurally novel PTP1B inhibitors with specific selectivity containing oxindole-fused spirotetrahydrofurochroman by one-pot reaction.Dong SZ, Lei YB, Jia SK, Gao LX, Li J, Zhu T, Liu SY* and Hu WH*. Bioorg Med Chem Lett (2017)27: 1105-1108·························································· 2.454 

 

国重尾模板----中国科学院上海药物研究所
版权所有 中国科学院上海药物研究所 沪ICP备 05005386号 地址: 上海市浦东张江祖冲之路555号 邮编:201203